244 related articles for article (PubMed ID: 9626024)
1. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome.
Termanini B; Gibril F; Sutliff VE; Yu F; Venzon DJ; Jensen RT
Am J Med; 1998 May; 104(5):422-30. PubMed ID: 9626024
[TBL] [Abstract][Full Text] [Related]
2. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.
Stewart CA; Termanini B; Sutliff VE; Serrano J; Yu F; Gibril F; Jensen RT
Aliment Pharmacol Ther; 1998 Jan; 12(1):83-98. PubMed ID: 9692706
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
4. Development of sustained achlorhydria in a patient with the Zollinger-Ellison syndrome treated with omeprazole.
Griffith JL; Cummings OW; Hirschowitz BI
Gastroenterology; 1991 Jul; 101(1):242-6. PubMed ID: 1796940
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
[TBL] [Abstract][Full Text] [Related]
6. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
[TBL] [Abstract][Full Text] [Related]
8. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors.
Hirschowitz BI; Worthington J; Mohnen J
Aliment Pharmacol Ther; 2008 Jun; 27(11):1110-21. PubMed ID: 18315582
[TBL] [Abstract][Full Text] [Related]
9. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
Jensen RT; Metz DC; Koviack PD; Feigenbaum KM
Aliment Pharmacol Ther; 1993; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
13. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
Lamers CB
Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
McArthur KE; Jensen RT; Gardner JD
Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
[TBL] [Abstract][Full Text] [Related]
17. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
Meijer JL; Jansen JB; Lamers CB
Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
[TBL] [Abstract][Full Text] [Related]
19. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor.
Ruscin JM; Page RL; Valuck RJ
Ann Pharmacother; 2002 May; 36(5):812-6. PubMed ID: 11978157
[TBL] [Abstract][Full Text] [Related]
20. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
Walan A
Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
